Benefits
Same-day performance on the hardest cognitive tasks (secondary finding)
In a 2026 randomized, double-blind, placebo-controlled parallel-group study, a single 300 mg dose did not beat placebo on the primary outcome, which was overall calmness. As a secondary result, participants taking Zensera performed better than placebo on the hardest executive function trials five hours after the dose. That is one secondary finding at one time point in one industry co-authored trial, so it is preliminary rather than established. The battery included attention network, task switching, rapid visual information processing, paced auditory serial addition and word recall tasks. The reported benefit was limited to the most demanding trials at the 5 hour time point, not spread across the battery.
Calmness: the outcome the trial was built around, and missed
Overall subjective calmness was the pre-specified primary aim of the trial, and it did not change versus placebo. The only calmness signal reported was a recovery pattern: after high-demand sessions, transient calmness returned in the Zensera group in a way not seen in the placebo group. That is a secondary observation, and the missed primary outcome is the more important fact. Zensera should not be presented as proven for stress or anxiety.
Long-term use has not been tested
Every published finding on Zensera comes from one acute test day after a single 300 mg dose, with measurements stopping at 5 hours. No study has examined daily or repeated use, and the trial authors wrote that research into chronic stress is still warranted. Any claim that benefits build with regular use is untested.
Mechanism of action
Stress-cognitive pathway botanical modulation
Zensera™'s lemon balm leaf extract is proposed to target the neurological pathways connecting stress response activation to cognitive performance impairment. Givaudan says the extract was selected by screening for GABA receptor activation and inhibition of GABA transaminase, with rosmarinic acid as the standardized marker compound. Those are laboratory findings. The human trial measured heart rate and blood pressure but no GABA or cortisol markers, so it did not test this mechanism. Further detail sits in Givaudan Taste and Wellbeing technical documentation rather than in peer-reviewed papers.
Clinical trials
Randomized, double-blind, placebo-controlled parallel-group study of a single 300 mg dose. The primary outcome, overall calmness, was not significant. A secondary cognitive result appeared at 5 hours.
106 healthy young adults with moderate subjective stress. Randomized, double-blind, placebo-controlled, parallel-group design. 300 mg Zensera™ (Givaudan patent-pending lemon balm extract from Melissa officinalis L.) vs matching placebo. Cognitive function, mood, heart rate and BP measured at baseline, 1, 3, and 5 hours post-treatment during cognitive overload tasks. NCT06183372 (LemCog trial, University of Reading).
Primary outcome (overall calmness) was not significant. Secondary findings: at 5 hours post-consumption, Zensera improved performance on the most demanding cognitive challenges vs placebo. Performance gains correlated with increased calmness and contentment. The trial also reported that transient calmness recovered after demanding sessions in the Zensera group but not in the placebo group. Measurements stopped at 5 hours, so nothing is known about effects beyond that point. Published in Therapeutic Advances in Psychopharmacology (doi 10.1177/20451253261415706, February 2026; PubMed PMID 41782777). Proposed mechanism from Givaudan laboratory screening, not measured in this trial: GABA receptor activation, GABA transaminase inhibition and rosmarinic acid absorption. Funding note: the study was funded by Givaudan France Naturals as part of a PhD studentship, and two of the seven authors work for Givaudan. There is no independent replication.